Novartis, US government reach agreement to lower drug prices

Under the agreement, Novartis has voluntarily committed to several actions. These include launching future medicines with prices comparable to those in other high-income countries; establishing direct-to-patient platforms for Tabrecta (capmatinib), Mayzent (siponimod), and Rydapt (midostaurin), with these platforms being accessible via TrumpRx.

Novartis will seek participation in the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) Model to further improve access to medicines for Medicaid patients.

The company will also support efforts to address the global imbalance in pharmaceutical innovation investment.

Novartis CEO Vas Narasimhan said: “This agreement continues our long-term partnership with the US government to advance the development and manufacturing of breakthrough treatments for patients in the United States.

“We are committed to working with governments worldwide to ensure innovation is appropriately valued and that our medicines reach the patients who need them most.”

Earlier this year, Novartis announced plans to invest $23bn over five years to expand its US research and manufacturing infrastructure.

Following this announcement, the company revealed plans for a $1.1bn biomedical research centre in San Diego, initiated construction of a flagship manufacturing hub with three facilities in the Raleigh/Durham area of North Carolina, and opened a radioligand therapy manufacturing plant in Carlsbad, California.

Additionally, Novartis is advancing plans for new radioligand therapy manufacturing facilities in Texas and Florida. As a result of these investments, the company anticipates receiving three years of tariff relief.

The post Novartis, US government reach agreement to lower drug prices appeared first on Pharmaceutical Business review.